Michael Geranen is the founder of Captura Biopharma. Captura Biopharma has raised $50M in total funding. Latest round: Growth. Based in Little Rock, AR.
Michael Geranen co-founded Captura Biopharma, a company focused on developing heavy metal chelators. Based in Little Rock, AR, Captura Biopharma's lead product, C2E2, was developed based on research at the University of North Carolina and has received funding from NIH grants and private investors. C2E2 is intended as an oral decorporation agent for radiation exposure and also has potential for treating heavy metal toxicity.
Full founder directory · Investor directory · Company funding database · Fundraising library